The efficacy and safety of rhC1‐INH for management of HAE attacks have been demonstrated in adolescents and adults in randomized, placebo‐controlled trials,21, 22 open‐label extension studies,23, 24, 25 and pooled analyses.26 In addition, data published in 2017 showed rhC1‐INH to be efficacious and well tolerated as prophylactic therapy in individuals aged 13 years or older with C1‐INH‐HAE.27 The objective of the current study was to evaluate the efficacy and safety of rhC1‐INH for acute treatment of HAE attacks in children. Here, SERPING1 is linked to hereditary angioedema.